NASDAQ: BDRXBiodexa Pharmaceuticals PLC Stock
$1.16-0.13 (-10.08%)
Updated Feb 20, 2026
BDRX Price
$1.16
Fair Value Price
$2.05
Market Cap
$0.00
52 Week Low
$1.04
52 Week High
$44.40
P/E
0x
P/B
0x
P/S
0.54x
PEG
N/A
Dividend Yield
N/A
Revenue
$1.05M
Earnings
-$33.80M
Gross Margin
100%
Operating Margin
-3,445.89%
Profit Margin
-3,171.6%
Debt to Equity
0.3
Operating Cash Flow
-$15M
Beta
1.01
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
BDRX Overview
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma. In addition, the company offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release therapeutics; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. It has collaboration agreements with Janssen and Melior. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine BDRX's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
BDRX
Ranked#256 of 478
Ranked#256 of 478
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $5.17 | A | |
| $7.45 | A | |
| $16.36 | A |
Be the first to know about important BDRX news, forecast changes, insider trades & much more!
BDRX News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how BDRX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BDRX ($1.16) is undervalued by 43.36% relative to our estimate of its Fair Value price of $2.05 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
BDRX ($1.16) is significantly undervalued by 43.36% relative to our estimate of its Fair Value price of $2.05 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
BDRX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more BDRX due diligence checks available for Premium users.
Valuation
BDRX fair value
Fair Value of BDRX stock based on Discounted Cash Flow (DCF)
Price
$1.16
Fair Value
$2.05
Undervalued by
43.36%
BDRX ($1.16) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
BDRX ($1.16) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
BDRX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
BDRX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
0x
Industry
211.15x
Market
44.63x
BDRX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0x
Industry
5.17x
BDRX's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
BDRX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
BDRX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$20.3M
Liabilities
$4.6M
Debt to equity
0.3
BDRX's short-term assets ($12.15M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BDRX's short-term assets ($12.15M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BDRX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
BDRX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
BDRX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
BDRX vs Biotech Stocks
Biodexa Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.